Papers/PMID:24905534
Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials.
Arthritis care & research2014The record
1 finding drawn from this paper, on 1 compound across 1 endpoint.
What it reported
How to read these marksWhat moved
1 finding
glucosamine — decreases osteoarthritis pain (pooled across scales)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×1“Glucosamine moderately reduced pain (SMD -0.51 [95% CI -0.72, -0.30]), although a high level of between-trial inconsistency was observed (I(2) = 88%).”
Quoted verbatim from Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials.. - Study
- meta-analysis
- Population
- Osteoarthritis patients, pooled across 25 placebo-controlled glucosamine trials
Effect -0.51 standardised mean difference, 95% CI -0.72 to -0.3